Nothing Special   »   [go: up one dir, main page]

WO2008007880A1 - A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases - Google Patents

A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases Download PDF

Info

Publication number
WO2008007880A1
WO2008007880A1 PCT/KR2007/003318 KR2007003318W WO2008007880A1 WO 2008007880 A1 WO2008007880 A1 WO 2008007880A1 KR 2007003318 W KR2007003318 W KR 2007003318W WO 2008007880 A1 WO2008007880 A1 WO 2008007880A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
polar solvent
solvent soluble
batsch
prunus persica
Prior art date
Application number
PCT/KR2007/003318
Other languages
French (fr)
Inventor
Won Yoon Chung
Sun Kyoung Lee
Kwang Kyun Park
Jae Kwan Hwang
Sang Kook Lee
Original Assignee
Industry-Academic Cooperation Foundation, Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry-Academic Cooperation Foundation, Yonsei University filed Critical Industry-Academic Cooperation Foundation, Yonsei University
Publication of WO2008007880A1 publication Critical patent/WO2008007880A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736Prunus, e.g. plum, cherry, peach, apricot or almond
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to composition comprising an extract of Prunus persica
  • Bone supports human soft tissues and body weight and protects inner organs such as intestines from outer impacts and shocks by surrounding inner organs. In addition to such supporting functions for muscles and intestines, it has an important function as a reservoir for essential body mineral components such as calcium, phosphorous and magnesium.
  • Inner organs such as intestines
  • it has an important function as a reservoir for essential body mineral components such as calcium, phosphorous and magnesium.
  • Essential body mineral components such as calcium, phosphorous and magnesium.
  • Adult bones with terminated growth are not static, and undergo a dynamic and continuous rebuilding process in which resorption and new bone formation occur. This process is called as bone remodeling (Yamaguchi A. et al., Tanpakushitsu Kakusan Koso., 50(6Suppl). pp. 664-669, 2005).
  • the bone turnover a process in which old bones are removed and replaced with new bones, is pivotal for the repair of micro-damage of bones associated with growth and stress and the maintenance of bone functions (Cohen-Solal M. et al., Therapie., 58f5I pp.391-393, 2003).
  • Bone remodeling has been reported to involve two types of cells. One of them is bone-forming osteoblasts and another is bone-resorbing osteoclasts. Osteoblasts produce RANKL (receptor activator of nuclear factor-kB ligand) and its decoy receptor, OPG (osteoprotegerin). RANKL binds to RANK (receptor activator of nuclear factor- kB) on osteoclast progenitor cells that are then maturated to osteoclasts, finally inducing bone-resorption. However, where OPG binds to RANKL to block the binding between RANKL and RANK, the formation of osteoclasts is inhibited and bone-resorption does not occur at undesirable level (Theill LE.
  • Osteoblasts produced in bone cells are involved in the filling of pores with collagen and covering of pores with precipitates of calcium and phosphorous (hydroxyapatite), thereby forming new bones to rebuild skeleton (Stains JP. et al., birth Defects Res C Embryo Today., 15(Y). pp.72-80, 2005). It takes about 100 days to disrupt old bones and rebuild new bones (Schwarz EM. Et al., Cwrr Opin Orthop., YV, pp. 329-335, 2000). While 100% of calcium content in bone is changed with 1 year in an infant, about 10-30% of the skeleton is rebuilt by the bone remodeling in an adult.
  • Osteoporosis is defined as a disease characterized by low bone mass and deterioration of bone microstructure, causing bone fragility and increased risk of fracture. The disease is developed by unbalanced remodeling exhibiting osteoclastic activities higher than osteoblastic activities (Iqbal MM., South Med J., 93Q). pp.2-18, 2000).
  • osteoporosis bone shows a widened space between structures and a thinner microarchitecture that becomes susceptible to skeletal fractures (Stephan JJ. Et al., Endocr Regul., 37(4 * ). pp.225-238, 2003).
  • Osteoporosis is classified into postmenopausal osteoporosis in which the bone loss (2-3% a year) appears upon initiation of menopause and the risk of spine compression and wrist bone fracture is elevated; senile osteoporosis in which it is developed slowly (0.5-1% a year) in elder men and women aged more than 70 years and induces gradual bone loss of hip and spine bones; and secondary osteoporosis developed by diseases ⁇ e.g., endocrine diseases, gastrointestinal diseases and cancer), drugs (e.g., adrenal cortical hormones, anticancer chemotherapy, thyroid hormones, anticonvulsants, antiplatelets, methotexate, cy- closporine and GnRH), alcohol, smoking or accidents (Rosen CJ., ⁇ Engl J Med., 353(6 * ). pp.595-603, 2005 ; Davidson M., Clinicain Reviews., 12(4 * ). pp.75-82, 2002).
  • the cancer cells entering bones proliferate in bone-surrounding microenvironments and stimulate the activity of osteoclasts or osteoblasts, thereby determining whether the subsequent bone metastasis is osteolytic or osteoblastic (Choong PF., et al., Clin Orthop RelatRes., 415S. pp. S19-S31, 2003).
  • Prunus persica (L.) BATSCH is originated from drainage area of Yellow River in
  • Prunus persica (L.) BATSCH of the present invention is generally classified into white peach and yellow peach.
  • the present inventors investigated the inhibitory effect of the extract or purified extract of white peach and yellow peach on the osteolysis of osteoclast induced by RANKL, and finally found that the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH shows potent inhibitory effect on the formation of osteoclast induced by RANKL as well as on the bone resorption by osteoclast without harmful effect on the cell viability of macrophage cells derived from mouse bone marrow therefore it can be used as the effective and safe therapeutics or health food for treating and preventing bone disease.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the treatment and prevention of bone disease as an active ingredient, together with a pharmaceutically acceptable carrier.
  • the present invention also provides a use of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the preparation of therapeutic agent for treating or preventing bone diseases in a mammal including human in need thereof.
  • the present invention also provides a health food comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an active ingredient for the alleviation and prevention of bone diseases.
  • a method for treating or preventing bone diseases comprising administering to mammal in an effective amount of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
  • the term "crude extract” disclosed herein comprise the extract which can be prepared by extracting plant material with at least one solvent selected from the group consisting of water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, ethyl acetate, ether and chloroform, preferably, the mixture of water and ethanol.
  • polar solvent soluble extract comprise the extract which can be prepared by fractionating above-described crude extract with polar solvent, for example, water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, or the mixture of thereof, preferably, butanol.
  • polar solvent for example, water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, or the mixture of thereof, preferably, butanol.
  • non-polar solvent soluble extract comprise the extract which can be prepared by extracting above-described crude extract with non-polar solvent, for example, ethyl acetate, hexane, chloroform or methylene chloride, preferably, ethyl acetate.
  • bone diseases includes various bone diseases caused by excessive formation of osteoclast induced by RANKL or excessive bone resorption of osteoclast, for example, osteoporosis, rheumatoid arthritis, osteoarthritis, degenerative arthritis, disk, osteomalacia, rickets or polyostotic fibrous dysplasia, preferably, osteoporosis.
  • extract of Prunus persica (L.) BATSCH comprises the extract of the flesh, peel or seed of Prunus persica (L.) BATSCH, preferably, the flesh or the peel of Prunus persica (L.) BATSCH.
  • An inventive extract of Prunus persica (L.) BATSCH can be prepared in detail by following procedures.
  • the flesh of Prunus persica (L.) BATSCH is washed with removing the seed, mixed with 1 to 40-fold, preferably, approximately 1 to 30-fold volume of water, C 1 to C 4 lower alcohols such as ethanol, methanol and the like, or the mixture of thereof, preferably, the mixture of water and ethanol with the mixed ratio ranging from about 1: 0.1 to 1: 10, more preferably, 70 to 100% ethanol or methanol in water; the solution is treated at the temperature ranging from 0 to 120°C, preferably, at the room temperature for the period ranging from 1 to 24 hours, preferably, 3 to 10 hours with extraction method by the extraction with hot water, cold water, reflux extraction or ultra-sonication extracton, preferably, reflux extraction and then dried by vacuum freeze-drying to obtain crude extract of Prunus persica (L.) BATSCH.
  • C 1 to C 4 lower alcohols such as ethanol, methanol and the like, or the mixture of thereof, preferably, the mixture of water and ethanol with the mixed
  • the polar solvent soluble and non-polar solvent soluble extract of present invention can be prepared by following procedure; the crude extract prepared by the above-described step, is suspended in water, and then is mixed with 1 to 100-fold, preferably, 1 to 5-fold volume of non-polar solvent soluble such as hexane, ethyl acetate, chloroform, ether and the like; the non-polar solvent soluble layer is collected to obtain non-polar solvent soluble extract of the present invention and remaining polar solvent soluble layer is collected to obtain polar solvent soluble extract of the present invention which is soluble in water, C to C lower alcohol such as methanol, ethanol, butanol and the like or the mixture thereof; the extract is collected with filtration, concentrated under reduced pressure and dried to obtain an inventive polar solvent soluble extract of Prunus persica (L.) BATSCH.
  • non-polar solvent soluble such as hexane, ethyl acetate, chloroform, ether and the like
  • the inventive composition for treating and preventing bone disease may comprises the above-described extract as 0.1 ⁇ 50 % by weight based on the total weight of the composition.
  • inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).
  • composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • pharmaceutically acceptable carriers e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl
  • the formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
  • compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the extract of the present invention can be formulated in the form of ointments and creams.
  • compositions containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
  • oral dosage form prowder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule
  • topical preparation cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like
  • injectable preparation solution, suspension, emulsion
  • composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.1 to 1000mg/kg, preferably, 1 to 100 mg/kg by weight/day of the inventive extract of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably, 0.5 to 40% by weight based on the total weight of the composition.
  • composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intra-cerebroventricular injection.
  • a health food or food additives comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH, together with a sitologically acceptable additive for the prevention and alleviation of bone diseases.
  • the health food of the present invention comprises the above-described extract as 0.01 to 80 %, preferably, 1 to 50 % by weight based on the total weight of the composition.
  • the health food of the present invention can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
  • the health food of the present invention comprises the above-described extract as
  • the food additive of the present invention can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
  • the present invention provide a composition of the health food beverage for the prevention and improvement of bone diseases adding 0.01 to 80 % the above-described extract by weight, 0.001 to 5 % amino acids by weight, 0.001 to 2 % vitamins by weight, 0.001 to 20 % sugars by weight, 0.001 to 10 % organic acids by weight and proper amount of sweetener and flavors.
  • examples of addable food comprising the above- described extract of the present invention are various food, beverage, gum, vitamin complex, health improving food and the like, and can be used as power, granule, tablet, chewing tablet, capsule or beverage etc.
  • the extract of the present invention will be able to prevent and alleviate bone disease by way of adding to child and infant food, such as modified milk powder, modified milk powder for growth period, modified food for growth period.
  • composition therein can be added to food, additive or beverage, wherein, the amount of above described extract in food or beverage may generally range from about 0.1 to 80w/w %, preferably, 1 to 50 w/w % of total weight of food for the health food composition and 1 to 30 g, preferably, 3 to 10 g on the ratio of IOOD of the health beverage composition.
  • the health beverage composition of present invention contains above described extract as an essential component in the indicated ratio
  • the other component can be various deodorant or natural carbohydrate etc such as conventional beverage.
  • natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cy- clodextrin; and sugar alcohol such as xylitol, and erythritol etc.
  • natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al.
  • the amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably, 5 to 12 g in the ratio of 100 D of present beverage composition.
  • the other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al.
  • the other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination.
  • the ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition.
  • Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health improving food and the like.
  • the inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • organic acid such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid
  • phosphate such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate
  • natural anti-oxidants such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • Prunus persica (L.) BATSCH of the present invention inhibited the formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.
  • Fig. 1 shows the effect of the ethanol extract of white peach and the purified fractions thereof on the cell viability of bone marrow macrophage cell derived from mice;
  • Fig. 2 shows the effect of the ethanol extract of yellow peach and the purified fractions thereof on the cell viability of bone marrow macrophage cell derived from mice;
  • Fig. 3 shows the inhibitory effect of the ethanol extract of flesh part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 5 shows the inhibitory effect of the ethanol extract of flesh part of yellow peach and the purified fractions thereof on the formation of osteoclast;
  • Fig. 6 shows the inhibitory effect of the ethanol extract of peel part of yellow peach and the purified fractions thereof on formation of osteoclast;
  • Fig. 7 shows the inhibitory effect of the ethanol extract of peel part of white peach and the butanol soluble fraction thereof on the bone resorption by osteoclast;
  • Fig. 8 shows the inhibitory effect of the ethyl acetate soluble fractions of flesh part and peel part of yellow peach on the bone resorption by osteoclast.
  • the collected residue was evaporated by rotary vacuum evaporator (Heidolph VV2011, Switzerland), dried with lyophilization to obtain various kinds of ethanol extract of peach, i.e., 14.05g of the peel extract of white peach, 13.6Og of the peel extract of white peach, 13.96g of the flesh extract of yellow peach, 13.75g of the peel extract of yellow peach respectively, to use as test samples in following experiments.
  • Example 1 The ethanol extract prepared in Example 1 was suspended in water and the suspension was fractionated with ethyl acetate, butanol and distilled water to afford ethyl acetate-soluble fraction, butanol-soluble fraction and water-soluble fraction of the present invention. The fractions were filtered and the filtrates were evaporated to obtain ethyl acetate-soluble fraction as a non-polar solvent soluble extract and the butanol-soluble fraction and water-soluble fraction as polar solvent soluble extract of the present invention.
  • Mouse bone marrow macrophage cell (1 x 10 4 cells) was added to each well of 96 well plates and cultured in ⁇ -MEM containing 1% of antibiotic-antimycotic solution, 10% of FBS (fetal bovine serum), 30 ng/ml of M-CSF (macrophage-colony stimulating factor), and the ethanol extract of flesh part of white peach, the ethanol extract of peel part of white peach, the ethyl acetate soluble fractions thereof, the butanol soluble fractions thereof, or the water soluble fractions thereof as test samples.
  • FBS fetal bovine serum
  • M-CSF macrophage-colony stimulating factor
  • test samples prepared in Example 1 and 2 were dissolved in DMSO (dimethyl sulfoxide) and water, and the solutions were diluted with 10% FBS- ⁇ -MEM to the concentration of 0, 1, 10, 100 D/ml.
  • the mouse bone marrow macrophage cells were cultured by changing with fresh new medium every 2 days, and incubated for 5 days at 37 °C in 5% CO incubator.
  • MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
  • the cell viability was calculated by the percentage ratio of absorbance of test sample groups comprising the extract ofPrunus persica (L.) BATSCH or the fraction thereof to the absorbance of control treated with only medium.
  • Mouse bone marrow macrophage cells were added to 96 well plates in a concentration of IxIO 4 cells per each well and incubated in 10% FBS- ⁇ -MEM containing RANKL (100 ng/ml), M-CSF (30 ng/ml), and 100 D/ml of the ethanol extract of flesh part or peel part of white peach or 100 D/ml of ethyl acetate-soluble fraction, butanol- soluble fraction, or water-soluble fraction of flesh part or peel part of white peach.
  • FBS- ⁇ -MEM containing RANKL 100 ng/ml
  • M-CSF 30 ng/ml
  • 100 D/ml of the ethanol extract of flesh part or peel part of white peach 100 D/ml of ethyl acetate-soluble fraction, butanol- soluble fraction, or water-soluble fraction of flesh part or peel part of white peach.
  • mice The mouse bone marrow macrophage cells separated from the hind legs of 4- weeks aged mice were added to 24 well plates coated with calcium phosphate with a concentration of 5xlO 4 cells per each well. 10% FBS- ⁇ -MEM containing RANKL (100 ng/ml), M-CSF (30 ng/ml), the ethanol extract of peel part of white peach (75, 100 D/ml) and butanol-soluble fraction of peel part of white peach (75, 100 D/ml) was added to each well.
  • FBS- ⁇ -MEM containing RANKL 100 ng/ml
  • M-CSF 30 ng/ml
  • the ethanol extract of peel part of white peach 75, 100 D/ml
  • butanol-soluble fraction of peel part of white peach 75, 100 D/ml
  • the ethyl acetate-soluble fraction of flesh part of yellow peach (10, 50 D/ml) and the ethyl acetate-soluble fraction of peel part of yellow peach (10, 50 D/ml) were added thereto to incubate for 15 days with changing fresh medium every 2 days. After the incubation, the medium was removed and sodium hypochlorite solution was added thereto. 5 minutes after the reaction, the sodium hypochlorite solution was removed and plate was washed with distilled water twice. The resorption pit formed by osteoclasts was observed by optical microscope.
  • Powder preparation was prepared by mixing above components and filling sealed package.
  • Tablet preparation was prepared by mixing above components and entabletting.
  • Capsule preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method. [140]
  • Injection preparation was prepared by dissolving the components in 2D ample and sterilizing by conventional injection preparation method. [147]
  • Vitamin mixture optimum amount
  • Health beverage preparation was prepared by dissolving active component, mixing, stirred at 85 0 C for 1 hour, filtered and then filling all the components in 2000D ample and sterilizing by conventional health beverage preparation method.
  • the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH of the present invention inhibited the formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH of the present invention inhibitedthe formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.

Description

Description
A COMPOSITION COMPRISING AN EXTRACT OF PRUNUS PERSICA (L.) BATSCH FOR TREATING AND PREVENTING
BONE DISEASES
Technical Field
[1] The present invention relates to composition comprising an extract of Prunus persica
(L.) BATSCH for treating and preventing bone diseases.
[2]
Background Art
[3] Bone supports human soft tissues and body weight and protects inner organs such as intestines from outer impacts and shocks by surrounding inner organs. In addition to such supporting functions for muscles and intestines, it has an important function as a reservoir for essential body mineral components such as calcium, phosphorous and magnesium. Adult bones with terminated growth are not static, and undergo a dynamic and continuous rebuilding process in which resorption and new bone formation occur. This process is called as bone remodeling (Yamaguchi A. et al., Tanpakushitsu Kakusan Koso., 50(6Suppl). pp. 664-669, 2005). The bone turnover, a process in which old bones are removed and replaced with new bones, is pivotal for the repair of micro-damage of bones associated with growth and stress and the maintenance of bone functions (Cohen-Solal M. et al., Therapie., 58f5I pp.391-393, 2003).
[4] Bone remodeling has been reported to involve two types of cells. One of them is bone-forming osteoblasts and another is bone-resorbing osteoclasts. Osteoblasts produce RANKL (receptor activator of nuclear factor-kB ligand) and its decoy receptor, OPG (osteoprotegerin). RANKL binds to RANK (receptor activator of nuclear factor- kB) on osteoclast progenitor cells that are then maturated to osteoclasts, finally inducing bone-resorption. However, where OPG binds to RANKL to block the binding between RANKL and RANK, the formation of osteoclasts is inhibited and bone-resorption does not occur at undesirable level (Theill LE. et al., Annu Rev Immunol, 20, pp.795-823, 2002; Wagner EF. et al., Cwrr Opin Genet Dev., 11, pp.527-532, 2001). Resorption or disruption of old bones is induced by osteoclasts generated in blood cells (hematopoietic cells), that allows a trace amount of calcium ions to be released into blood circulation by forming pores on bones to contribute to mineral homeostasis (William J. et al., Nature., 423. pp.337-342, 2003). Osteoblasts produced in bone cells are involved in the filling of pores with collagen and covering of pores with precipitates of calcium and phosphorous (hydroxyapatite), thereby forming new bones to rebuild skeleton (Stains JP. et al., Birth Defects Res C Embryo Today., 15(Y). pp.72-80, 2005). It takes about 100 days to disrupt old bones and rebuild new bones (Schwarz EM. Et al., Cwrr Opin Orthop., YV, pp. 329-335, 2000). While 100% of calcium content in bone is changed with 1 year in an infant, about 10-30% of the skeleton is rebuilt by the bone remodeling in an adult. Only if the two processes, resorption and bone formation are quantitatively equal, the bone mass can be maintained. Where such remodeling process becomes unbalanced, a variety of diseases or disorders such as osteoporosis and damages associated with bone metastasis of cancer cells are caused. Osteoporosis is defined as a disease characterized by low bone mass and deterioration of bone microstructure, causing bone fragility and increased risk of fracture. The disease is developed by unbalanced remodeling exhibiting osteoclastic activities higher than osteoblastic activities (Iqbal MM., South Med J., 93Q). pp.2-18, 2000). While the inner structure of normal bones has a compact network, the osteoporosis bone shows a widened space between structures and a thinner microarchitecture that becomes susceptible to skeletal fractures (Stephan JJ. Et al., Endocr Regul., 37(4*). pp.225-238, 2003). Osteoporosis is classified into postmenopausal osteoporosis in which the bone loss (2-3% a year) appears upon initiation of menopause and the risk of spine compression and wrist bone fracture is elevated; senile osteoporosis in which it is developed slowly (0.5-1% a year) in elder men and women aged more than 70 years and induces gradual bone loss of hip and spine bones; and secondary osteoporosis developed by diseases {e.g., endocrine diseases, gastrointestinal diseases and cancer), drugs (e.g., adrenal cortical hormones, anticancer chemotherapy, thyroid hormones, anticonvulsants, antiplatelets, methotexate, cy- closporine and GnRH), alcohol, smoking or accidents (Rosen CJ., Η Engl J Med., 353(6*). pp.595-603, 2005 ; Davidson M., Clinicain Reviews., 12(4*). pp.75-82, 2002).
[5] Breast cancer, prostate cancer and multiple myeloma are accompanied with bone metastasis (Kozlow W. et al., J Mannary Gland Biol Neoplasia., 10(2), pp. 169-180, 2005). The life span of patients having such cancer has been suggested to be dependent on bone metastasis. The bone metastasis observed in breast cancer cells do not affect directly bone but stimulates osteoclasts (Boyde A. et al., Scan Electron Microsc, 4, pp.1537-1554, 1986). Unlikely, the bone metastasis found in prostate cancer is an osteoblastic metastasis. The osteoblastic metastasis has been also reported to relate directly to osteolysis. The cancer cells entering bones proliferate in bone-surrounding microenvironments and stimulate the activity of osteoclasts or osteoblasts, thereby determining whether the subsequent bone metastasis is osteolytic or osteoblastic (Choong PF., et al., Clin Orthop RelatRes., 415S. pp. S19-S31, 2003).
[6] Prunus persica (L.) BATSCH is originated from drainage area of Yellow River in
China, grown in the Korea, America, Italy and Spain. It has been known that the peel, leaf, flower, fruit, seed of downy peach together with peach worm has been used as an oriental medicine since long years ago. Persicae semen has been reported to comprise glyceride, sterol, emulsin and amygdalin and to show inhibitory effect on Oketsu (Kosuge T., Chem. Pharm. Bull, 33, pp.1496-1498, 1985), to be closely involved in anti-tumor promoter and thereby is used as a therapeutic for treating women's diseases (Fukuda, T., Biol. Pharm. Bull, 26, pp.271-273, 2003).
[7] Prunus persica (L.) BATSCH of the present invention is generally classified into white peach and yellow peach. The present inventors investigated the inhibitory effect of the extract or purified extract of white peach and yellow peach on the osteolysis of osteoclast induced by RANKL, and finally found that the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH shows potent inhibitory effect on the formation of osteoclast induced by RANKL as well as on the bone resorption by osteoclast without harmful effect on the cell viability of macrophage cells derived from mouse bone marrow therefore it can be used as the effective and safe therapeutics or health food for treating and preventing bone disease.
[8]
Disclosure of Invention Technical Problem
[9] The present invention provides a pharmaceutical composition comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the treatment and prevention of bone disease as an active ingredient, together with a pharmaceutically acceptable carrier.
[10] The present invention also provides a use of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the preparation of therapeutic agent for treating or preventing bone diseases in a mammal including human in need thereof.
[11] The present invention also provides a health food comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an active ingredient for the alleviation and prevention of bone diseases.
[12]
Technical Solution
[13] Accordingly, it is an object of the present invention to provide a pharmaceutical composition comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for treating or preventing bone diseases as an effective ingredient, together with a pharmaceutically acceptable carrier.
[14] In accordance with another aspect of the present invention, there is also provided a use of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the preparation of therapeutic agent for treating or preventing bone diseases in a mammal including human in need thereof.
[15] In accordance with the other aspect of the present invention, there is also provided a method for treating or preventing bone diseases comprising administering to mammal in an effective amount of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
[16] The term "crude extract" disclosed herein comprise the extract which can be prepared by extracting plant material with at least one solvent selected from the group consisting of water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, ethyl acetate, ether and chloroform, preferably, the mixture of water and ethanol.
[17] The term "polar solvent soluble extract" disclosed herein comprise the extract which can be prepared by fractionating above-described crude extract with polar solvent, for example, water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, or the mixture of thereof, preferably, butanol.
[18] The term "non-polar solvent soluble extract" disclosed herein comprise the extract which can be prepared by extracting above-described crude extract with non-polar solvent, for example, ethyl acetate, hexane, chloroform or methylene chloride, preferably, ethyl acetate.
[19] The term "bone diseases" disclosed herein includes various bone diseases caused by excessive formation of osteoclast induced by RANKL or excessive bone resorption of osteoclast, for example, osteoporosis, rheumatoid arthritis, osteoarthritis, degenerative arthritis, disk, osteomalacia, rickets or polyostotic fibrous dysplasia, preferably, osteoporosis.
[20] The term "extract of Prunus persica (L.) BATSCH" disclosed herein comprises the extract of the flesh, peel or seed of Prunus persica (L.) BATSCH, preferably, the flesh or the peel of Prunus persica (L.) BATSCH.
[21]
[22] Hereinafter, the present invention is described in detail.
[23]
[24] An inventive extract of Prunus persica (L.) BATSCH can be prepared in detail by following procedures.
[25]
[26] For example, the flesh of Prunus persica (L.) BATSCH is washed with removing the seed, mixed with 1 to 40-fold, preferably, approximately 1 to 30-fold volume of water, C 1 to C 4 lower alcohols such as ethanol, methanol and the like, or the mixture of thereof, preferably, the mixture of water and ethanol with the mixed ratio ranging from about 1: 0.1 to 1: 10, more preferably, 70 to 100% ethanol or methanol in water; the solution is treated at the temperature ranging from 0 to 120°C, preferably, at the room temperature for the period ranging from 1 to 24 hours, preferably, 3 to 10 hours with extraction method by the extraction with hot water, cold water, reflux extraction or ultra-sonication extracton, preferably, reflux extraction and then dried by vacuum freeze-drying to obtain crude extract of Prunus persica (L.) BATSCH.
[27] Additionally, the polar solvent soluble and non-polar solvent soluble extract of present invention can be prepared by following procedure; the crude extract prepared by the above-described step, is suspended in water, and then is mixed with 1 to 100-fold, preferably, 1 to 5-fold volume of non-polar solvent soluble such as hexane, ethyl acetate, chloroform, ether and the like; the non-polar solvent soluble layer is collected to obtain non-polar solvent soluble extract of the present invention and remaining polar solvent soluble layer is collected to obtain polar solvent soluble extract of the present invention which is soluble in water, C to C lower alcohol such as methanol, ethanol, butanol and the like or the mixture thereof; the extract is collected with filtration, concentrated under reduced pressure and dried to obtain an inventive polar solvent soluble extract of Prunus persica (L.) BATSCH.
[28] Also, the above-described procedures may be modified or subjected to further step to fractionate or isolate more potent fractions or compounds by conventional procedure well-known in the art, for example, the procedure disclosed in the literature (Harborne J.B. Phytochemical method; A guide to modern thchniques of plant analysis, 3r Ed. Pp. 6-7, 1998).
[29] It is an object of the present invention to provide a method of treating or preventing bone disease in mammal or human comprising administering to said mammal or human with an effective amount of an extract of Prunus persica (L.) BATSCH together with a pharmaceutically acceptable carrier thereof.
[30] The inventive composition for treating and preventing bone diseasemay comprises the above-described extract as 0.1 ~ 50 % by weight based on the total weight of the composition.
[31] The inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing co, Easton PA).
[32] Hereinafter, the following formulation methods and excipients are merely exemplary and in no way limit the invention.
[33] The composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
[34] For example, the compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection. Suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them. For topical administration, the extract of the present invention can be formulated in the form of ointments and creams.
[35] Pharmaceutical formulations containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
[36] The composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
[37] The desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 0.1 to 1000mg/kg, preferably, 1 to 100 mg/kg by weight/day of the inventive extract of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably, 0.5 to 40% by weight based on the total weight of the composition.
[38] The pharmaceutical composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intra-cerebroventricular injection.
[39] Also, it is another object of the present invention to provide a health food or food additives comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH, together with a sitologically acceptable additive for the prevention and alleviation of bone diseases. The health food of the present invention comprises the above-described extract as 0.01 to 80 %, preferably, 1 to 50 % by weight based on the total weight of the composition.
[40] The health food of the present invention can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
[41] The health food of the present invention comprises the above-described extract as
0.01 to 80 %, preferably, 1 to 50 % by weight based on the total weight of the composition.
[42] The food additive of the present invention can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
[43] Also, the present invention provide a composition of the health food beverage for the prevention and improvement of bone diseases adding 0.01 to 80 % the above-described extract by weight, 0.001 to 5 % amino acids by weight, 0.001 to 2 % vitamins by weight, 0.001 to 20 % sugars by weight, 0.001 to 10 % organic acids by weight and proper amount of sweetener and flavors.
[44] To develop for health food, examples of addable food comprising the above- described extract of the present invention are various food, beverage, gum, vitamin complex, health improving food and the like, and can be used as power, granule, tablet, chewing tablet, capsule or beverage etc.
[45] Also, the extract of the present invention will be able to prevent and alleviate bone disease by way of adding to child and infant food, such as modified milk powder, modified milk powder for growth period, modified food for growth period.
[46] The above-described composition therein can be added to food, additive or beverage, wherein, the amount of above described extract in food or beverage may generally range from about 0.1 to 80w/w %, preferably, 1 to 50 w/w % of total weight of food for the health food composition and 1 to 30 g, preferably, 3 to 10 g on the ratio of IOOD of the health beverage composition.
[47] Providing that the health beverage composition of present invention contains above described extract as an essential component in the indicated ratio, there is no particular limitation on the other liquid component, wherein the other component can be various deodorant or natural carbohydrate etc such as conventional beverage. Examples of aforementioned natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cy- clodextrin; and sugar alcohol such as xylitol, and erythritol etc. As the other deodorant than aforementioned ones, natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al., may be useful favorably. The amount of above described natural carbohydrate is generally ranges from about 1 to 20 g, preferably, 5 to 12 g in the ratio of 100 D of present beverage composition.
[48] The other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al. The other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination. The ratio of the components is not so important but is generally range from about 0 to 20 w/w % per 100 w/w % present composition. Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health improving food and the like.
[49] The inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, α- tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
[50]
Advantageous Effects
[51] The crude extract, polar solvent soluble or non-polar solvent soluble extract of
Prunus persica (L.) BATSCH of the present invention inhibited the formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.
[52]
Brief Description of the Drawings
[53] The above and other objects, features and other advantages of the present invention will more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which;
[54]
[55] Fig. 1 shows the effect of the ethanol extract of white peach and the purified fractions thereof on the cell viability of bone marrow macrophage cell derived from mice; [56] [57] Fig. 2 shows the effect of the ethanol extract of yellow peach and the purified fractions thereof on the cell viability of bone marrow macrophage cell derived from mice; [58] [59] Fig. 3 shows the inhibitory effect of the ethanol extract of flesh part of white peach and the purified fractions thereof on the formation of osteoclast; [60] [61] Fig. 4 shows the inhibitory effect of the ethanol extract of peel part of white peach and the purified fractions thereof on the formation of osteoclast; [62] [63] Fig. 5 shows the inhibitory effect of the ethanol extract of flesh part of yellow peach and the purified fractions thereof on the formation of osteoclast; [64] [65] Fig. 6 shows the inhibitory effect of the ethanol extract of peel part of yellow peach and the purified fractions thereof on formation of osteoclast; [66] [67] Fig. 7 shows the inhibitory effect of the ethanol extract of peel part of white peach and the butanol soluble fraction thereof on the bone resorption by osteoclast; [68] [69] Fig. 8 shows the inhibitory effect of the ethyl acetate soluble fractions of flesh part and peel part of yellow peach on the bone resorption by osteoclast. [70]
Best Mode for Carrying Out the Invention [71] It will be apparent to those skilledin the art that various modifications and variations can be made in the compositions, use and preparations of the present invention without departing from the spirit or scope of the invention. [72]
Mode for the Invention [73] The present invention is more specifically explained by the following examples.
However, it should be understood that the present invention is not limited to these examples in any manner. [74]
[75] Example 1. Preparation of the ethanol extract of Prunus persica (L.) BATSCH
[76] White peach and yellow peach of the present invention was purchased from
Kyeonggi Dong-boo Fruit Agricultural Cooperative located at Icheon in Korea. [77] The peach was washed with removing the seed, separated into flesh and peel and dried with lyophilization. The flesh part and peel part of peach was mixed with 80% ethanol with the ratio of 1:5 (w/v) and the mixture was subjected to reflux extraction for 48 hours, 3 times. The solution was filtered with filter paper No.2 (Advantec TOYO, Japan) and the filtrate was collected. The collected residue was evaporated by rotary vacuum evaporator (Heidolph VV2011, Switzerland), dried with lyophilization to obtain various kinds of ethanol extract of peach, i.e., 14.05g of the peel extract of white peach, 13.6Og of the peel extract of white peach, 13.96g of the flesh extract of yellow peach, 13.75g of the peel extract of yellow peach respectively, to use as test samples in following experiments.
[78]
[79] Example 2. Preparation of the polar solvent and non-polar solvent extract of
Primus pcrsica (L.) BATSCH
[80] The ethanol extract prepared in Example 1 was suspended in water and the suspension was fractionated with ethyl acetate, butanol and distilled water to afford ethyl acetate-soluble fraction, butanol-soluble fraction and water-soluble fraction of the present invention. The fractions were filtered and the filtrates were evaporated to obtain ethyl acetate-soluble fraction as a non-polar solvent soluble extract and the butanol-soluble fraction and water-soluble fraction as polar solvent soluble extract of the present invention.
[81] All the fractions prepared from the above-described method were stored at -20°C to use as test samples.
[82]
[83] Experimental Example 1. Cell toxicity test of white peach extract
[84] In order to examine the cell toxicity test using by the ethanol extract ofPrunus persica (L.) BATSCH and the fraction thereof prepared in Example 1 and 2, following experiment was performed according to the method disclosed in the literature (Wattel A. et al., J. Cell Biochem., VI(IY pp.285-295, 2004).
[85] Mouse bone marrow macrophage cell (1 x 104 cells) was added to each well of 96 well plates and cultured in α-MEM containing 1% of antibiotic-antimycotic solution, 10% of FBS (fetal bovine serum), 30 ng/ml of M-CSF (macrophage-colony stimulating factor), and the ethanol extract of flesh part of white peach, the ethanol extract of peel part of white peach, the ethyl acetate soluble fractions thereof, the butanol soluble fractions thereof, or the water soluble fractions thereof as test samples. The test samples prepared in Example 1 and 2 were dissolved in DMSO (dimethyl sulfoxide) and water, and the solutions were diluted with 10% FBS-α-MEM to the concentration of 0, 1, 10, 100 D/ml. The mouse bone marrow macrophage cells were cultured by changing with fresh new medium every 2 days, and incubated for 5 days at 37 °C in 5% CO incubator. MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was added thereto to the concentration of 5 mg/ml per each well. After culturing for 4 hours at 37 °C, the medium and MTT solution were removed and then 200 D of DMSO per each well was added thereto. 20 minutes after the reaction, the absorbance was measured at 570nm. The cell viability was calculated by the percentage ratio of absorbance of test sample groups comprising the extract ofPrunus persica (L.) BATSCH or the fraction thereof to the absorbance of control treated with only medium.
[86] As can be seen in Tables 1, 2 and Fig. 1, the cell viability of the groups treated with the ethyl acetate-soluble fraction and the butanol-soluble fraction of flesh part of white peach; and the ethyl acetate-soluble fraction of peel part of white peach in the concentration of 100D/ml were reduced by 21%, 13% and 61% respectively (IC of the
50 ethyl acetate-soluble fraction of peel part of white peach = 90.24 D/ml). However, the ethanol extract and butanol-soluble fraction and water soluble fraction of flesh part of white peach; and the butanol-soluble fraction and water-soluble fraction of peel part of white peach in the concentration of 0-100 D/ml did not show any effect on the cell viability of the mouse bone marrow macrophage cell. [87] Table 1
[Table 1] [Table ]
Figure imgf000013_0001
[88] Table 2
[Table 2] [Table ]
Figure imgf000014_0001
[89] [90] Experimental Example 2. Cell toxicity test of the extract of yellow peach [91] In order to examine the cell toxicity test using by the ethanol extract of yellow peach and the fractions thereof prepared in Example 1 and 2, following experiment was performed according to procedure similar to procedure disclosed in the Experimental Example 1.
[92] As can be seen in Tables 3, 4 and Fig. 2, the cell viability of the groups treated with the ethyl acetate-soluble fraction of flesh part and peel part of yellow peach were reduced by 25%, and 27% respectively. However, the ethanol extract and butanol- soluble fraction and water soluble fraction of flesh part and peel part of yellow peach in the concentration of 0-100 D/ml did not show any effect on the cell viability of the mouse bone marrow macrophage cell.
[93] Table 3 [Table 3] [Table ]
Figure imgf000015_0001
[94] Table 4
[Table 4] [Table ]
Figure imgf000016_0001
[95] [96] Experimental Example 3. The inhibitory effect of the extract of white peach on the formation of osteoclasts
[97] In order to examine the inhibitory effect of the extract and the fractions of white peach prepared in Example 1 and 2 on the formation of osteoclasts isolated from mouse bone marrow macrophage, following experiments were performed according to the method disclosed in the literature (Park EK. et al., Biochem Biophys Res Commun., 325f4I pp.1472- 1480, 2004).
[98] Mouse bone marrow macrophage cells were added to 96 well plates in a concentration of IxIO4 cells per each well and incubated in 10% FBS-α-MEM containing RANKL (100 ng/ml), M-CSF (30 ng/ml), and 100 D/ml of the ethanol extract of flesh part or peel part of white peach or 100 D/ml of ethyl acetate-soluble fraction, butanol- soluble fraction, or water-soluble fraction of flesh part or peel part of white peach. 75, 100 D/ml of ethanol extract of peel part of white peach and 75, 100 D/ml of ethyl acetate- soluble fraction, butanol-soluble fraction or water-soluble fraction of peel part of white peach were incubated in 10% FBS-α-MEM. The group treated with only 10% FBS- α-MEM was used as control. The cells were cultured with changing fresh medium every 2 days for 5 days and then the formation of osteoclasts was examined by staining with TRAP analysis kit (tartrate-resistant acid phosphatase assay kit; Sigma, MO, USA). The number of cells containing more than three nuclei was counted by using optical microscope.
[99] As can be seen in Table 5 and Fig. 3, the number of osteoclasts treated with RANKL were significantly increased whereas the mouse bone marrow macrophage cells not- treated with RANKL did not form osteoclast cells (p<0.00001). The mouse bone marrow macrophage cells treated with the ethanol extract of flesh part of white peach and various fractions of flesh part of white peach inhibited the formation of RANKL- induced osteoclasts by 24.5% (p<0.05). The mouse bone marrow macrophage cells treated with the ethanol extract of peel part of white peach and various fractions of peel part of white peach inhibited the formation of RANKL-induced osteoclasts in a dose dependent manner (ethanol extract: p<0.05, butanol-soluble fraction: p<0.001) as can be seen in Table 6 and Fig. 4. It is confirmed that the ethyl acetate-soluble fraction of peel part of white peach completely inhibit the formation of osteoclast and such result is assumed that the fraction significantly reduced the cell viability of mouse bone marrow macrophage cells resulting in blocking of osteoclast differentiation.
[100] Table 5 [Table 5] [Table ]
Figure imgf000017_0001
[101] Table 6 [Table 6] [Table ]
Figure imgf000018_0001
[102]
[103] Experimental Example 4. The inhibitory effect of yellow peach extract on the formation of osteoclasts
[104] In order to examine the inhibitory effect of the extract and fractions of yellow peach prepared in Example 1 and 2 on the formation of osteoclasts isolated from mouse bone marrow macrophage, following experiments were performed according to the method similar to the procedure disclosed in the Experimental Example 3.
[105] 100 D/ml of the ethanol extract, ethyl acetate-soluble fraction, butanol-soluble fraction or water-soluble fraction of flesh part of yellow peach were treated to mouse bone marrow macrophage cells respectively and 75, 100 D/ml of the ethanol extract and 75, 100 D/ml of ethyl acetate-soluble fraction, butanol-soluble fraction or water-soluble fraction of peel part of yellow peach were treated in 10% FBS-α-MEM to incubate for 5 days. The number of osteoclasts was determined.
[106] As can be seen in Tables 7, 8 and Figs. 5 and 6, the number of osteoclasts treated with RANKL were significantly increased whereas the mouse bone marrow macrophage cells not-treated with RANKL did not form osteoclast cell(p<0.00001). the ethanol extract and various fractions of flesh part and peel part of yellow peach significantly decreased the formation of osteoclasts (p<0.0001).
[107] Table 7 [Table 7] [Table ]
Figure imgf000019_0001
[108] Table 8 [Table 8] [Table ]
Figure imgf000019_0002
[109] [HO] Experimental Example 5. Determination of bone resorption by osteoclasts [111] In order to examine the effect of the extract and fractions of yellow peach prepared in Example 1 and 2 on the bone resorption induced by RANKL in mouse bone marrow macrophage cells, following experiments were performed according to the method disclosed in the literature (Wattel A. et al., J. Cell Biochem., 92f2*>. pp.285-295, 2004).
[112] The ethanol extract and butanol-soluble fraction of peel part of white peach and ethyl acetate-soluble fraction of flesh part and peel part of yellow peach showing potent inhibiting activity of the formation of osteoclasts induced by RANKL were adopted as test samples in the experiment.
[113] The mouse bone marrow macrophage cells separated from the hind legs of 4- weeks aged mice were added to 24 well plates coated with calcium phosphate with a concentration of 5xlO4 cells per each well. 10% FBS-α-MEM containing RANKL (100 ng/ml), M-CSF (30 ng/ml), the ethanol extract of peel part of white peach (75, 100 D/ml) and butanol-soluble fraction of peel part of white peach (75, 100 D/ml) was added to each well. The ethyl acetate-soluble fraction of flesh part of yellow peach (10, 50 D/ml) and the ethyl acetate-soluble fraction of peel part of yellow peach (10, 50 D/ml) were added thereto to incubate for 15 days with changing fresh medium every 2 days. After the incubation, the medium was removed and sodium hypochlorite solution was added thereto. 5 minutes after the reaction, the sodium hypochlorite solution was removed and plate was washed with distilled water twice. The resorption pit formed by osteoclasts was observed by optical microscope.
[114] As can be seen in Fig. 7 the ethanol extract of peel part of white peach and the butanol-soluble fraction of peel part of white peach significantly inhibited the formation of resorption pit in a does dependent manner.
[115] As can be seen in Fig. 8, the ethyl acetate-soluble fractions of flesh part and peel part of yellow peach significantly inhibited the formation of resorption pit in does dependent manner.
[116]
[117]
[118] Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. The representative preparation examples were described as follows.
[119]
[120]
[121] Preparation of powder
[ 122] Extract of Prunus persica (L.) BATSCH of Example 1 20mg
[123] Lactose lOOmg
[124] Talc lOmg
[125] Powder preparation was prepared by mixing above components and filling sealed package.
[126]
[127] Preparation of tablet
[ 128] Extract of Prunus persica (L.) BATSCH of Example 1 1 Omg
[ 129] Corn Starch 1 OOmg [130] Lactose lOOmg
[131] Magnesium Stearate 2mg
[132] Tablet preparation was prepared by mixing above components and entabletting.
[133]
[134] Preparation of capsule
[135] Extract of Prunus persica (L.) BATSCH of Example 1 1 Omg
[136] Corn Starch 3mg
[137] Lactose 14.8mg
[138] Magnesium Stearate 0.2mg
[139] Capsule preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method. [140]
[141] Preparation of injection
[142] Extract of Prunus persica (L.) BATSCH of Example 1 lOmg
[143] Mannitol 180mg
[ 144] Distilled water for inj ection 2974mg
[145] Na2HPO4, 12H2O 26mg
[146] Injection preparation was prepared by dissolving the components in 2D ample and sterilizing by conventional injection preparation method. [147]
[148] Preparation of health care food
[149] Extract of Prunus persica (L.) BATSCH of Example 1 lOOOmg
[150] Vitamin mixture optimum amount
[151] Vitamin A acetate 70mg
[152] Vitamin E l. Omg
[153] Vitamin B1 0.13mg
[154] Vitamin B 0.15mg
[155] Vitamin B6 0.5mg
[156] Vitamin B 12 0.2mg
[157] Vitamin C l Omg
[158] Biotin lOmg
[159] Amide nicotinic acid 1.7mg
[160] Folic acid 50mg
[161] Calcium pantothenic acid 0.5mg
[162] Mineral mixture optimum amount
[163] Ferrous sulfate 1.75mg
[ 164] Zinc oxide 0.82mg
[165] Magnesium carbonate 25.3mg [166] Monopotassium phosphate 15mg
[167] Dicalcium phosphate 55mg
[168] Potassium citrate 90mg
[169] Calcium carbonate lOOmg
[170] Magnesium chloride 24.8mg
[171] The above mentioned vitamin and mineral mixture may be varied in may ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention.
[172]
[173] Preparation of health beverage
[ 174] Extract of Prunus persica (L.) BATSCH of Example 1 1 OOOmg
[175] Citric acid lOOOmg
[176] Oligosaccharide lOOg
[177] Apricot concentration 2g
[178] Taurine Ig
[179] Concentrated plum solution 2g
[ 180] Distilled water 900D
[181] Health beverage preparation was prepared by dissolving active component, mixing, stirred at 850C for 1 hour, filtered and then filling all the components in 2000D ample and sterilizing by conventional health beverage preparation method.
[182]
[183] The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the present invention, and all such modifications as would be obvious to one skilled in the art are intended to be included within the scope of the following claims.
[184]
Industrial Applicability
[185] As described in the above, the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH of the present invention inhibited the formation of osteoclasts in mouse bone marrow macrophages treated with RANKL and the bone resorption by osteoclasts without harmful effect on the viability of mouse bone marrow macrophage cells. Accordingly, it can be used as the therapeutics or health food for treating and preventing bone diseases.

Claims

Claims
[1] A pharmaceutical composition comprising the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for treating or preventing bone diseases as an effective ingredient, together with a pharmaceutically acceptable carrier.
[2] The pharmaceutical composition of claim 1, wherein said extract is extracted from the flesh part or peel part of Prunus persica (L.) BATSCH.
[3] The pharmaceutical composition of claim 1, wherein said crude extract is prepared by extracting plant material with at least one solvent selected from the group consisting of water, C 1 to C 4 lower alcohol such as methanol, ethanol and the like, ethyl acetate, ether and chloroform.
[4] The pharmaceutical composition of claim 1, wherein said polar solvent soluble extract is prepared by fractionating said crude extract with water or C to C lower alcohol.
[5] The pharmaceutical composition of claim 1, wherein said non-polar solvent soluble extract is prepared by fractionating said crude extract with ethyl acetate, hexane, chloroform or methylene chloride.
[6] The pharmaceutical composition of claim 1, wherein said bone disease is osteoporosis, rheumatoid arthritis, osteoarthritis, degenerative arthritis, disk, osteomalacia, rickets or polyostotic fibrous dysplasia.
[7] A use of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH for the preparation of therapeutic agent for treating or preventing bone diseases in a mammal including human in need thereof.
[8] A method for treating or preventing bone diseases comprising administering to mammal in an effective amount of the crude extract, polar solvent soluble or non-polar solvent soluble extract of Prunus persica (L.) BATSCH as an effective ingredient, together with a pharmaceutically acceptable carrier thereof.
[9] A health care food comprising the crude extract, polar solvent soluble or non- polar solvent soluble extract of Prunus persica (L.) BATSCH, together with a sitologically acceptable additive for prevention and alleviation of bone diseases.
[10] The health care food according to claim 9 wherein said health care food is provided as powder, granule, tablet, capsule or beverage type.
PCT/KR2007/003318 2006-07-14 2007-07-09 A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases WO2008007880A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2006-0066236 2006-07-14
KR1020060066236A KR100823354B1 (en) 2006-07-14 2006-07-14 A composition comprising an extract of Prunus persica L. Batsch for treating and preventing bone disease

Publications (1)

Publication Number Publication Date
WO2008007880A1 true WO2008007880A1 (en) 2008-01-17

Family

ID=38923409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/003318 WO2008007880A1 (en) 2006-07-14 2007-07-09 A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases

Country Status (2)

Country Link
KR (1) KR100823354B1 (en)
WO (1) WO2008007880A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704765B1 (en) 2016-05-06 2017-02-08 주식회사 금시조 The peachtree extract pill and tea for improvement of thyroid deseases
KR101924532B1 (en) * 2016-09-07 2018-12-03 연세대학교 산학협력단 A pharmaceutical composition for treating or prevebting bon disease
KR102186886B1 (en) * 2018-07-11 2020-12-04 한국 한의학 연구원 Composition for preventing, ameliorating or treating osteoporosis containing Prunus jamasakura extract as effective component

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010067023A (en) * 2000-12-13 2001-07-12 류희영 Curing agents for born porosity symptom, arthralgia and arthritis, and the manufacturing method thereof
JP2002338485A (en) * 2001-05-22 2002-11-27 Hideko Iizuka Method for preparation of juice for treatment of disease
KR100518686B1 (en) * 2001-06-26 2005-11-08 한국 한의학 연구원 Extract of herb for promoting release of growth hormone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010067023A (en) * 2000-12-13 2001-07-12 류희영 Curing agents for born porosity symptom, arthralgia and arthritis, and the manufacturing method thereof
JP2002338485A (en) * 2001-05-22 2002-11-27 Hideko Iizuka Method for preparation of juice for treatment of disease
KR100518686B1 (en) * 2001-06-26 2005-11-08 한국 한의학 연구원 Extract of herb for promoting release of growth hormone

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARJMANDI B.H. ET AL.: "Dried plums improve indices of bone formation in postmenopausal women", J. WOMENS HEALTH GEND. BASED MED., vol. 11, no. 1, 2002, pages 61 - 68, XP009056026, DOI: doi:10.1089/152460902753473471 *
DEYHIM F. ET AL.: "Dried plum reverses bone loss in an osteopenic rat model of osteoporosis", MENOPAUSE, vol. 12, no. 6, 2005, pages 755 - 762 *

Also Published As

Publication number Publication date
KR100823354B1 (en) 2008-04-17
KR20080006907A (en) 2008-01-17

Similar Documents

Publication Publication Date Title
US10980842B2 (en) Composition for promotng bone formation with fermented oysters and seaweed
KR101686490B1 (en) Composition comprising extract of black rice as an effective component for prevention or treatment of metabolic bone disease
KR20080099362A (en) Composition comprising an extract of processed ginseng for preventing and treating obesity
JP6026639B2 (en) Composition for prevention and treatment of bone metabolic disease containing extract of genus Fujibacama and method for producing the same
KR102081984B1 (en) A pharmaceutical composition comprising extract from wheat sprowt for preventing or treating osteoporosis
KR101039053B1 (en) Compositions for Treatment and Prevention of Bone Diseases Comprising Extract of Hypericum ascyron
KR101451755B1 (en) A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Mori Fructus and Aralia Continentalis
KR20240134840A (en) Composition for promoting osteoblast differentiation comprising anthocyanin
KR102286429B1 (en) A composition for improving, preventing and treating bone-related disease comprising polysaccharide fraction isolated from Nelumbo nucifera leaf
WO2008007880A1 (en) A composition comprising an extract of prunus persica (l.) batsch for treating and preventing bone diseases
KR101444760B1 (en) A composition for preventing bone metabolism-related diseases and increasing bone function comprising mix extracts of Achyranthes bidentata and Siegesbeckia glabrescens
KR102372440B1 (en) Phamaceutical Composition Comprising an Extract of Artemisia scoparia for Preventing or Treating Metabolic Bone Disease-induced Bone Loss
KR101249930B1 (en) Compositions comprising extracts of Sorbus commixta and Geranium nepalense for inhibiting osteoclastogenesis and stimulating chondrogenesis
KR101052501B1 (en) Composition for the prevention and treatment of bone diseases containing herbal extract as an active ingredient
KR20160057525A (en) composition for the prevention and treatment ofosteoporosis containing Acyranthes bidentata Blume and ginseng extract
KR102448913B1 (en) Composition comprising extract of Abeliophyllum distichum for prevention or treatment of bone diseases
KR101972657B1 (en) Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating osteoporosis
KR101120499B1 (en) Composition For Preventing And Treating Bone Diseases
KR101910099B1 (en) Compositions for improving lipid metabolism or anti-obesity as an active ingredient extracted from an immature persimmon by pressurized hydrothermal method
KR102151643B1 (en) Composition comprising extract of Lentinula edodes for prevention or treatment of bone diseases
KR100832520B1 (en) A composition for the treatment or prevention of osteoporosis comprising an extract of capsosiphon fulvecense
KR101885667B1 (en) Extract of Oryza sativa for promoting osteoblast differentiation and its use
KR20150105561A (en) Pharmaceutical composition for preventing or treating bone disease comprising Hovenia dulcis Thunb extract
KR101753057B1 (en) Pharmaceutical composition for prevention or treatment of cognitive dysfunction or degenerative brain disease
KR102160627B1 (en) Pharmaceutical composition for preventing or treating bone disease comprising extracts of branches of Hovenia dulcis Thunb

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07768659

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07768659

Country of ref document: EP

Kind code of ref document: A1